Lincomycin

Paul G. Auwaerter, M.D.

INDICATIONS

FDA

  • Treatment of serious infections caused by susceptible strains of streptococci, pneumococci, and staphylococci in PCN-allergic patients.
  • Only IV formulation is available in the U.S.

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2025 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.